Hypertension Research最新文献

{"title":"Long-term risk of cardiovascular mortality according to age group and blood pressure categories of the latest guideline","authors":"Michihiro Satoh, Takayoshi Ohkubo, Katsuyuki Miura, Akiko Harada, Anna Tsutsui, Atsushi Hozawa, Yuji Shimizu, Shizukiyo Ishikawa, Yoshihiro Kokubo, Tomonori Okamura, Yoshitaka Murakami, on behalf of the Evidence for Cardiovascular Prevention from Observational Cohorts in Japan (EPOCH–JAPAN) Research Group","doi":"10.1038/s41440-025-02151-w","DOIUrl":"10.1038/s41440-025-02151-w","url":null,"abstract":"This study examined the association between the latest blood pressure (BP) classification and cardiovascular disease (CVD) mortality risk, using data from 70,570 individuals across 10 Japanese cohorts. Participants were stratified by age (40–64 and 65–89 years) and antihypertensive treatment use. BP was classified according to the 2019 Japanese Society of Hypertension Guidelines. During a follow-up period of approximately 10 years, 2304 CVD deaths occurred. Cox models demonstrated that CVD mortality risk increased stepwise with the BP category, with this association being especially pronounced in patients aged 40–64 years, where the Grade I hypertension group showed the highest population-attributable fraction (PAF). When the treated participants were included in the hypertension group, the overall PAF for CVD mortality was 41.1%. Similar patterns were observed for CVD subtype mortality risk, with hypertension showing particularly high PAFs for intracerebral hemorrhage. These findings highlight the importance of early-stage prevention and management of hypertension.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"48 4","pages":"1428-1433"},"PeriodicalIF":4.3,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41440-025-02151-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term visit-to-visit blood pressure variability and risk of cardiovascular and bleeding events: insights from the ENGAGE AF-TIMI 48 trial","authors":"Riccardo Proietti, Michael Gerard Palazzolo, Christian T. Ruff, Gregory Y. H. Lip, Robert P. Giugliano","doi":"10.1038/s41440-024-02083-x","DOIUrl":"10.1038/s41440-024-02083-x","url":null,"abstract":"This post hoc analysis of the ENGAGE AF-TIMI 48 trial assesses differences in cardiovascular and bleeding events according to visit-to-visit blood pressure variability (BPv) in 19,680 patients with a minimum of 4 blood pressure measurements post randomization. Patients were categorized into four groups based on the standard deviation of systolic blood pressure (SBP-SD). In comparisons of the fourth vs first quartile of SBP-SD adjusted for components of the CHA2D2-VASc score and baseline SBP, there were no differences in the odds of stroke, cardiovascular mortality, or all-cause mortality. However, there were statistically significant increases in the risk of major bleeding (OR 1.9, (1.6–2.25)). myocardial infarction (OR 1.42 (1.08–1.87)) and heart failure outcomes (OR 1.49 (1.3–1.72)) in the fourth quartile of BPv. This post-hoc analysis shows that BPv is independently associated with an increased risk of bleeding, MI, and heart failure outcomes in a population with AF on oral anticoagulation.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"48 4","pages":"1613-1618"},"PeriodicalIF":4.3,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41440-024-02083-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To prove the efficacy of OSAS treatment to improve the prognosis of patients with OSAS related hypertension","authors":"Shin-ichi Ando","doi":"10.1038/s41440-025-02153-8","DOIUrl":"10.1038/s41440-025-02153-8","url":null,"abstract":"","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"48 4","pages":"1440-1441"},"PeriodicalIF":4.3,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41440-025-02153-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined effects of hypertension and arterial stiffness on target organ damage among community-based screening participants","authors":"Yoshitsugu Sunagawa, Akio Ishida, Masanobu Yamazato, Yusuke Ohya, Kenya Kusunose","doi":"10.1038/s41440-025-02163-6","DOIUrl":"10.1038/s41440-025-02163-6","url":null,"abstract":"We investigated the impact of hypertension and high pulse wave velocity (PWV), each assessed in a single measurement, on target organ damage, proteinuria, and left ventricular hypertrophy (LVH). This observational cross-sectional study included 13,186 patients who underwent brachial-ankle PWV (baPWV) measurement, urinalysis, and electrocardiography during a health check-up. Blood pressure (BP) was measured at the time of baPWV measurement. Proteinuria and LVH were evaluated using a urine dipstick test and electrocardiography, respectively. Participants were categorized into four groups based on their hypertension (yes/no, defined as BP ≥ 140/90 mmHg) and baPWV (high/low, cutoff value of 14.0 m/s) statuses. The mean age of the participants was 53 ± 11 years, and the prevalence of proteinuria and LVH was 594 (4.5%) and 1716 (13.0%), respectively. Compared with the non-hypertension with low baPWV group, the non-hypertension with high baPWV (odds ratio [OR] 1.41 [95% confidence interval (CI), 1.07–1.86]), hypertension with low baPWV (OR 2.66 [95% CI, 1.78–3.97]), and hypertension with high baPWV groups (OR 2.80 [95% CI, 2.18–3.61]) exhibited a higher multivariate-adjusted risk for proteinuria. The hypertension with low baPWV group had a significantly higher risk of proteinuria than the non-hypertension with high baPWV group. Similar results were obtained for LVH. Hypertension and a high baPWV were independently associated with the prevalence of proteinuria and LVH. Hypertension assessed in a single BP measurement is likely to be a more important risk factor for proteinuria and LVH than high baPWV. Hypertension and high brachial-ankle pulse wave velocity were independently associated with the prevalence of proteinuria and left ventricular hypertrophy. Hypertension assessed in a single blood pressure measurement is likely to be a more important risk factor for proteinuria and left ventricular hypertrophy than high brachial-ankle pulse wave velocity.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"48 4","pages":"1342-1350"},"PeriodicalIF":4.3,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modifiable factors to achieve target blood pressure in hypertensive participants","authors":"Sachiko Tanaka-Mizuno, Fumiko Nakatsu, Shunsuke Eguchi, Kazuma Iekushi, Hironori Nakagami","doi":"10.1038/s41440-025-02134-x","DOIUrl":"10.1038/s41440-025-02134-x","url":null,"abstract":"The management of hypertension is one of the most important public health issues. Many patients with untreated hypertension in Japan require urgent treatment. This retrospective cohort study in Hiratsuka city aimed to evaluate the proportion of participants achieving target blood pressure and identify modifiable factors affecting the achievement. We retrospectively analyzed data from a merged database of claims, specific health checkup (SHC), and national health insurance data in Hiratsuka City, Japan, from June 2016 to March 2023. The study participants were adults aged 40–74 years without a history of hypertension treatment and with blood pressure ≥140/90 mmHg at SHC. The primary outcome was the achievement of target blood pressure <140/90 mmHg at the next SHC. Furthermore, multivariable logistic regression was performed to explore factors influencing the achievement. Of 5428 participants, 43.6% were female. The median age was 69 years, and 58.4% (95% confidence interval 57.1–59.7) achieved target blood pressure <140/90 mmHg. Multivariable logistic regression results showed that achievement of target blood pressure was associated with younger age (50–69 years), mild hypertension (grade I), no hypertension at the previous SHC, no record of SHC in the previous year, and willingness to improve lifestyle. One-third of people reported that their hypertension at SHCs failed to achieve target blood pressure. For community-level hypertension management, people who have the influencing factors must be educated by public health nurses, which might be effective for lifestyle improvement. Additionally, the elderly and people with persistent hypertension or severe hypertension should seek medical advice.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"48 4","pages":"1295-1304"},"PeriodicalIF":4.3,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41440-025-02134-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nighttime blood pressure in patients with chronic kidney disease: ambulatory blood pressure monitoring status in Japan and future implementation","authors":"Michihiro Satoh, Hiroki Nobayashi, Shingo Nakayama, Metoki Hirohito","doi":"10.1038/s41440-025-02159-2","DOIUrl":"10.1038/s41440-025-02159-2","url":null,"abstract":"","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"48 4","pages":"1437-1439"},"PeriodicalIF":4.3,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41440-025-02159-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new mechanism of diabetic kidney disease progression by Piezo proteins: mediators between mechanical stimuli and fibrosis","authors":"Yuichi Yoshida, Hirotaka Shibata","doi":"10.1038/s41440-025-02162-7","DOIUrl":"10.1038/s41440-025-02162-7","url":null,"abstract":"Glomerular hypertrophy promotes fibrosis by activating Piezo proteins.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"48 4","pages":"1619-1620"},"PeriodicalIF":4.3,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41440-025-02162-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalised hypertension management with accurate blood pressure measurement: much achieved, much more to do","authors":"James E. Sharman","doi":"10.1038/s41440-025-02155-6","DOIUrl":"10.1038/s41440-025-02155-6","url":null,"abstract":"","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"48 4","pages":"1663-1666"},"PeriodicalIF":4.3,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41440-025-02155-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenomics and transcriptomics association study of blood pressure and incident diagnosis of hypertension in twins","authors":"Asmus Cosmos Skovgaard, Afsaneh M. Nejad, Hans Christian Beck, Qihua Tan, Mette Soerensen","doi":"10.1038/s41440-025-02164-5","DOIUrl":"10.1038/s41440-025-02164-5","url":null,"abstract":"Hypertension is the most frequent health-related condition worldwide and is a primary risk factor for renal and cardiovascular diseases. However, the underlying molecular mechanisms are still poorly understood. To uncover these mechanisms, multi-omics studies have significant potential, but such studies are challenged by genetic and environmental confounding – an issue that can be effectively reduced by studying intra-pair differences in twins. Here, we coupled data on hypertension diagnoses from the nationwide Danish Patient Registry to a study population of 740 twins for whom genome-wide DNA methylation and gene expression data were available together with measurements of systolic and diastolic blood pressure. We investigated five phenotypes: incident hypertension cases, systolic blood pressure, diastolic blood pressure, hypertension (140/90 mmHg), and hypertension (130/80 mmHg). Statistical analyses were performed using Cox (incident cases) or linear (remaining) regression analyses at both the individual-level and twin pair-level. Significant genes (p < 0.05) at both levels and in both types of biological data were investigated by bioinformatic analyses, including gene set enrichment analysis and interaction network analysis. Overall, most of the identified pathways related to the immune system, particularly inflammation, and biology of vascular smooth muscle cell. Of specific genes, lysine methyltransferase 2 A (KMT2A) was found to be central for incident hypertension, ataxia-telangiectasia mutated (ATM) for systolic blood pressure, and beta-actin (ACTB) for diastolic blood pressure. Noteworthy, lysine methyltransferase 2A (KMT2A) was also identified in the systolic and diastolic blood pressure analyses. Here, we present novel biomarkers for hypertension. This study design is surprisingly rare in the field of hypertension. We identified biological pathways related to vascular smooth muscle cells and the immune system, particular inflammation, to be associated with hypertension and blood pressure. Of specific genes, we identified KMT2A (lysine methyltransferase 2A) to be central for blood pressure and hypertension development. Abbreviations: ACTB: beta-actin, ATM: ataxia-telangiectasia mutated, BP: blood pressure, EWAS: epigenome-wide association studies, KMT2A: lysine methyltransferase 2A, LMER: linear mixed effect regression, LR: linear regression, TWAS: transcriptome-wide association studies.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"48 4","pages":"1599-1612"},"PeriodicalIF":4.3,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41440-025-02164-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood pressure elevations post-lenvatinib treatment in hepatocellular carcinoma: a potential marker for better prognosis","authors":"Keisuke Shibata, Yuichi Akasaki, Akihiro Tokushige, Mina Nitta, Shin Kawasoe, Takuro Kubozono, Kohei Oda, Kotaro Kumagai, Seiichi Mawatari, Mitsuru Ohishi","doi":"10.1038/s41440-025-02149-4","DOIUrl":"10.1038/s41440-025-02149-4","url":null,"abstract":"Lenvatinib is a tyrosine kinase inhibitor that effectively inhibits vascular endothelial growth factor signaling and is used for treating hepatocellular carcinoma. However, angiogenesis inhibitors often cause hypertension. Although lenvatinib-induced hypertension has been proposed as a potential surrogate marker for better prognosis, studies on blood pressure elevations and outcomes following lenvatinib initiation are limited. This study included 67 patients who underwent lenvatinib therapy at the Department of Gastroenterology, Kagoshima University Hospital, between May 2018 and December 2023. The median age of the cohort was 71 years, and 82.1% of the patients were male. The median blood pressure at admission was 128/73 mmHg, which significantly increased to 136/76 mmHg the day after lenvatinib administration. Grade 3 hypertension (≥160/100 mmHg) occurred in 37.3% of patients during hospitalization. The median increase in systolic blood pressure from admission to its peak during hospitalization was 26 mmHg. Patients who experienced an increase in blood pressure of ≥26 mmHg were classified into the blood pressure elevation group, which showed a significantly lower mortality rate than that of the blood pressure non-elevation group (35.3% vs. 81.8%, log-rank p = 0.007), even after adjusting for age, sex, disease stage, performance status, and liver reserve function. This study demonstrated that patients who experienced earlier blood pressure elevation after lenvatinib administration had lower overall mortality rates. These findings suggest that blood pressure elevations after lenvatinib initiation may serve as valuable prognostic indicators in patients with cancer undergoing lenvatinib therapy.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"48 4","pages":"1542-1553"},"PeriodicalIF":4.3,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41440-025-02149-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}